Keywords: EMEA, GlaxoSmithKline, Rotarix, Medicines network, Pharmacovigilance

EMEA sees no safety concerns with GlaxoSmithKline’s Rotarix oral vaccine; emphasises the importance of the European medicines network

Article | 29 March 2010

Print This

The European Medicines Agency (EMEA) says it has concluded that the unexpected presence of DNA of a non-disease causing viral ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in